MX378940B - Trastornos neurodegenerativos. - Google Patents

Trastornos neurodegenerativos.

Info

Publication number
MX378940B
MX378940B MX2017006692A MX2017006692A MX378940B MX 378940 B MX378940 B MX 378940B MX 2017006692 A MX2017006692 A MX 2017006692A MX 2017006692 A MX2017006692 A MX 2017006692A MX 378940 B MX378940 B MX 378940B
Authority
MX
Mexico
Prior art keywords
neurodegenerative disorders
therapies
disease
compositions
methods
Prior art date
Application number
MX2017006692A
Other languages
English (en)
Other versions
MX2017006692A (es
Inventor
Gwenael Pottiez
Sara Esther Garcia-Rates
Susan Adele Greenfield
Original Assignee
Neuro Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro Bio Ltd filed Critical Neuro Bio Ltd
Publication of MX2017006692A publication Critical patent/MX2017006692A/es
Publication of MX378940B publication Critical patent/MX378940B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)

Abstract

La invención se refiere a nuevos péptidos, composiciones, terapias y métodos para tratar trastornos neurodegenerativos, por ejemplo enfermedad de Alzheimer.
MX2017006692A 2014-11-26 2015-11-26 Trastornos neurodegenerativos. MX378940B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1420986.0A GB2539161A (en) 2014-11-26 2014-11-26 Neurodegenerative disorders
PCT/GB2015/053601 WO2016083809A1 (en) 2014-11-26 2015-11-26 Neurodegenerative disorders

Publications (2)

Publication Number Publication Date
MX2017006692A MX2017006692A (es) 2017-08-21
MX378940B true MX378940B (es) 2025-03-10

Family

ID=52292544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006692A MX378940B (es) 2014-11-26 2015-11-26 Trastornos neurodegenerativos.

Country Status (12)

Country Link
US (1) US10729749B2 (es)
EP (2) EP4116415A1 (es)
JP (1) JP6708646B2 (es)
KR (1) KR102489620B1 (es)
CN (2) CN114410606A (es)
AU (1) AU2015352182B2 (es)
BR (1) BR112017011226A2 (es)
ES (1) ES2925550T3 (es)
GB (1) GB2539161A (es)
MX (1) MX378940B (es)
RU (1) RU2707191C2 (es)
WO (1) WO2016083809A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2546773B (en) * 2016-01-28 2020-06-17 Neuro Bio Ltd Cancer
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
WO2019229771A2 (en) * 2018-06-01 2019-12-05 Council Of Scientific And Industrial Research Nonapeptide of formula i, pharmaceutical compositions and methods for preparation thereof
GB202004804D0 (en) * 2020-04-01 2020-05-13 Neuro Bio Ltd Skin
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses
CN113698454B (zh) * 2021-09-01 2022-05-24 北京林业大学 一种核桃粕乙酰胆碱酯酶抑制肽及其制备方法与应用
GB202306078D0 (en) 2023-04-25 2023-06-07 Neuro Bio Ltd Neurodegenerative disorders
GB202306126D0 (en) 2023-04-26 2023-06-07 Neuro Bio Ltd Treatment of rapamycin-sensitive conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606040D0 (en) * 1996-03-22 1996-05-22 Isis Innovation Active peptide
IL131707A0 (en) * 1999-05-31 2001-03-19 Yissum Res Dev Co Acetylcholinesterase-derived peptides and uses thereof
GB9930825D0 (en) * 1999-12-30 2000-02-16 Synaptica Limited Animal models for neurodegenerative disease
GB2364385B (en) * 2000-03-29 2002-08-14 Synaptica Ltd Alpha 7 nicotinic receptor screening assays
US20030092613A1 (en) * 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
GB0028578D0 (en) * 2000-11-23 2001-01-10 Synaptica Ltd Screening assays
EP1756272A2 (en) * 2004-01-09 2007-02-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
WO2007049281A1 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ache polypeptides, polynucleotides encoding same and compositions and methods of using same
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
GB0708646D0 (en) * 2007-05-04 2007-06-13 Enkephala Ltd Biologically active C-terminal fragment of acetylcholinesterase
PL2245056T4 (pl) * 2008-01-22 2016-01-29 Araim Pharmaceuticals Inc Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek
WO2012110953A1 (en) * 2011-02-16 2012-08-23 Novartis Ag Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
WO2013020366A1 (zh) * 2011-08-08 2013-02-14 中国科学院上海生命科学研究院 乙酰胆碱酯酶作为核酸酶的应用
WO2013148325A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
GB2516045A (en) * 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
GB201505239D0 (en) * 2015-03-27 2015-05-13 Neuro Bio Ltd Antibody

Also Published As

Publication number Publication date
MX2017006692A (es) 2017-08-21
AU2015352182A1 (en) 2017-06-29
RU2017121836A (ru) 2018-12-26
WO2016083809A1 (en) 2016-06-02
AU2015352182B2 (en) 2020-06-11
US10729749B2 (en) 2020-08-04
BR112017011226A2 (pt) 2018-03-27
CA2968933A1 (en) 2016-06-02
CN107001419B (zh) 2022-02-25
CN107001419A (zh) 2017-08-01
KR102489620B1 (ko) 2023-01-16
RU2707191C2 (ru) 2019-11-25
GB201420986D0 (en) 2015-01-07
JP6708646B2 (ja) 2020-06-10
EP3224270B1 (en) 2022-06-08
US20170266265A1 (en) 2017-09-21
JP2018506506A (ja) 2018-03-08
CN114410606A (zh) 2022-04-29
ES2925550T3 (es) 2022-10-18
EP4116415A1 (en) 2023-01-11
EP3224270A1 (en) 2017-10-04
KR20170104457A (ko) 2017-09-15
GB2539161A (en) 2016-12-14
RU2017121836A3 (es) 2019-05-28

Similar Documents

Publication Publication Date Title
IL285722A (en) Methods for treating alzheimer's disease
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX378940B (es) Trastornos neurodegenerativos.
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
EA202092435A3 (ru) Моноклональные антитела против bcma
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
IL269174A (en) Methods for treating complement-mediated diseases and disorders
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
IL263433A (en) Methods for treating alzheimer's disease
GEP20227382B (en) Anti-coagulation factor xi antibodies
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
DK3463351T3 (da) Behandling til parkinsons sygdom
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX382453B (es) Composiciones y metodos para tratar enfermedades neurodegenerativas
JO3628B1 (ar) كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
MX2019001804A (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
WO2016150415A8 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
EP3244897A4 (en) Methods for treating alzheimer's disease
BR112016021408A2 (pt) métodos para o tratamento da doença de alzheimer utilizando compostos derivados de 6-estradiol substituído
EA201700060A1 (ru) Терапевтическое средство для кератоконъюнктивальных расстройств
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
ME03056B (me) Jedinjenja 3,4-diamino-6-hloropirazin-2-karboksamida za tretman bolesti posredovanih sa enac
GB201614863D0 (en) Alzheimer's disease